Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Our team has reviewed this compound across hundreds of research protocols
Research Characteristics: Tripeptidecopper complex studied for its role in cellular signaling and biological regulation Investigated for activity in collagen synthesis pathways and tissue remodeling Examined in laboratory research for effects on oxidative stress and inflammatory balance THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only
Manipulation of gut microbiota influences immune responses, axon preservation, and motor disability in a model of progressive multiple sclerosis
Our science-backed treatments also support cellular health to help you live longer and feel younger
Pre-existing inborn errors of sulfur-amino-acid metabolism (e.g., homocystinuria) represent an absolute contraindication because parenteral methionine can exacerbate elevated homocysteine concentrations and associated thrombotic risk